Novel therapies and targets have transformed the management of psoriatic arthritis and related skin disease psoriasis. The successful introduction and widespread use of anti-IL17, anti-IL12/23 and anti-PDE4 strategies have joined the ranks of TNF inhibitors. Novel biological insights into specific disease mechanisms are co-emerging with this new wave of treatment options. The different available treatments allow the community to further focus on optimal patient management aiming at remission or minimal disease activity. Yet, the assessment of the patient and his/her satisfaction with current health status remains challenging. Treat to target initiatives are trying to define optimal care and cure adapted to the specific characteristics of the disease. Molecular knowledge of the disease processes remains scattered and insufficient to build a comprehensive view on the disease for the individual patient that would allow the personalized definition of effective strategies.
Disclosure of Interest R. Lories Grant/research support from: Celgene, Boehringer-Ingelheim, UCB, Consultant for: Janssen, Celgene, Novartis, Pfizer, UCB, Abbvie, Speakers bureau: Janssen, Celgene, Novartis, Pfizer, Merck, UCB, Abbvie